Limits...
Adventures in public data.

Zaharevitz DW - J Cheminform (2011)

Bottom Line: We, the Editors, wish to make clear however that this is an exception that we made because we would like to preserve the temporal unity and message of this set of publications.Insisting on a formal publication would have meant losing this historical account as part of the thematic series of papers or disrupting the series.We hope that this will find the consent of our readership.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Cancer Institute/NIH, Bethesda, Maryland, USA. zaharevd@mail.nih.gov.

ABSTRACT
This article contains the slides and transcript of a talk given by Dan Zaharevitz at the "Visions of a Semantic Molecular Future" symposium held at the University of Cambridge Department of Chemistry on 2011-01-19. A recording of the talk is available on the University Computing Service's Streaming Media Service archive at http://sms.cam.ac.uk/media/1095515 (unfortunately the first part of the recording was corrupted, so the talk appears to begin at slide 6, 'At a critical time'). We believe that Dan's message comes over extremely well in the textual transcript and that it would be poorer for serious editing. In addition we have added some explanations and references of some of the concepts in the slides and text. (Charlotte Bolton; Peter Murray-Rust, University of Cambridge) EDITORIAL PREFACE: The following paper is part of a series of publications which arose from a Symposium held at the Unilever Centre for Molecular Informatics at the University of Cambridge to celebrate the lifetime achievements of Peter Murray-Rust. One of the motives of Peter's work was and is a better transport and preservation of data and information in scientific publications. In both respects the following publication is relevant: it is about public data and their representation, and the publication represents a non-standard experiment of transporting the content of the scientific presentation. As you will see, it consists of the original slides used by Dan Zaharevitz in his talk "Adventures in Public Data" at the Unilever Centre together with a diligent transcript of his speech. The transcribers have gone through great effort to preserve the original spirit of the talk by preserving colloquial language as it is used at such occasions. For reasons known to us, the original speaker was unable to submit the manuscript in a more conventional form. We, the Editors, have discussed in depth whether such a format is suitable for a scientific journal. We have eventually decided to publish this "as is". We did this mostly because it was Peter's wish that this talk was published in this form and because we agreed with his notion that this format transmits the message just as well as a formal article as defined by our instructions for authors. We, the Editors, wish to make clear however that this is an exception that we made because we would like to preserve the temporal unity and message of this set of publications. Insisting on a formal publication would have meant losing this historical account as part of the thematic series of papers or disrupting the series. We hope that this will find the consent of our readership.

No MeSH data available.


Related in: MedlinePlus

Other Data.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198951&req=5

Figure 15: Other Data.

Mentions: (Figure 15) Other data. We have our NCI screening data-this is growth inhibition in human tumour cell lines. We have this both as calculated parameters from a full dose response curve, and as a full dose response curve. I mentioned molecular target data: there's microarray of gene expression in vivo in xenografts, which I think could be very important; that data is not quite public yet but it should be soon. We have in vivo survival screens curves from those old mouse model screens, so if anybody's interested in developing software or display tools for looking at survival curves we probably have something like 200 or 250 thousand survival curves. That's publicly available.


Adventures in public data.

Zaharevitz DW - J Cheminform (2011)

Other Data.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198951&req=5

Figure 15: Other Data.
Mentions: (Figure 15) Other data. We have our NCI screening data-this is growth inhibition in human tumour cell lines. We have this both as calculated parameters from a full dose response curve, and as a full dose response curve. I mentioned molecular target data: there's microarray of gene expression in vivo in xenografts, which I think could be very important; that data is not quite public yet but it should be soon. We have in vivo survival screens curves from those old mouse model screens, so if anybody's interested in developing software or display tools for looking at survival curves we probably have something like 200 or 250 thousand survival curves. That's publicly available.

Bottom Line: We, the Editors, wish to make clear however that this is an exception that we made because we would like to preserve the temporal unity and message of this set of publications.Insisting on a formal publication would have meant losing this historical account as part of the thematic series of papers or disrupting the series.We hope that this will find the consent of our readership.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Cancer Institute/NIH, Bethesda, Maryland, USA. zaharevd@mail.nih.gov.

ABSTRACT
This article contains the slides and transcript of a talk given by Dan Zaharevitz at the "Visions of a Semantic Molecular Future" symposium held at the University of Cambridge Department of Chemistry on 2011-01-19. A recording of the talk is available on the University Computing Service's Streaming Media Service archive at http://sms.cam.ac.uk/media/1095515 (unfortunately the first part of the recording was corrupted, so the talk appears to begin at slide 6, 'At a critical time'). We believe that Dan's message comes over extremely well in the textual transcript and that it would be poorer for serious editing. In addition we have added some explanations and references of some of the concepts in the slides and text. (Charlotte Bolton; Peter Murray-Rust, University of Cambridge) EDITORIAL PREFACE: The following paper is part of a series of publications which arose from a Symposium held at the Unilever Centre for Molecular Informatics at the University of Cambridge to celebrate the lifetime achievements of Peter Murray-Rust. One of the motives of Peter's work was and is a better transport and preservation of data and information in scientific publications. In both respects the following publication is relevant: it is about public data and their representation, and the publication represents a non-standard experiment of transporting the content of the scientific presentation. As you will see, it consists of the original slides used by Dan Zaharevitz in his talk "Adventures in Public Data" at the Unilever Centre together with a diligent transcript of his speech. The transcribers have gone through great effort to preserve the original spirit of the talk by preserving colloquial language as it is used at such occasions. For reasons known to us, the original speaker was unable to submit the manuscript in a more conventional form. We, the Editors, have discussed in depth whether such a format is suitable for a scientific journal. We have eventually decided to publish this "as is". We did this mostly because it was Peter's wish that this talk was published in this form and because we agreed with his notion that this format transmits the message just as well as a formal article as defined by our instructions for authors. We, the Editors, wish to make clear however that this is an exception that we made because we would like to preserve the temporal unity and message of this set of publications. Insisting on a formal publication would have meant losing this historical account as part of the thematic series of papers or disrupting the series. We hope that this will find the consent of our readership.

No MeSH data available.


Related in: MedlinePlus